![We Care for Every Heartbeat]({"type":"image" , "src" : "/sda/112416/JournalAd-TACD-Daiichi.jpg"})
https://orcid.org/0000-0003-1078-9095
References
- Choe JC, Oh J-H, Lee HC, et al. The effect of nicorandil on cardiac function and clinical outcomes in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: a randomised trial. Acta Cardiol. 2023:1–9.
- Şaylık F, Akbulut T. The association of PRECISE-DAPT score with thrombus burden in patients with ST-segment elevation myocardial infarction. Acta Cardiol. 2022;77(5):449–455.
- Güler A, Gürbak İ, Panç C, et al. Frequency and predictors of no-reflow phenomenon in patients with COVID-19 presenting with ST-segment elevation myocardial infarction. Acta Cardiol. 2022;77(4):313–321.
- Hahn J-Y, Song YB, Oh J-H, SMART-DATE İnvestigators, et al. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial. Lancet. 2018;391(10127):1274–1284.
- Qian G, et al. Effects of nicorandil administration on ınfarct size in patients with ST-segment-elevation myocardial ınfarction undergoing primary percutaneous coronary ıntervention: the CHANGE trial. Circ Cardiovasc Interv. 2019;12(11):e008233.
![Committed to improving the lives of patients with Type 2 Diabetes, Heart Failure and Chronic Kidney Disease.]({"type":"image" , "src" : "/sda/112387/JournalAd-TACD-BOEHR-MPU.jpg"})
![Bristol Myers Squibb – symposium on hypertrophic cardiomyopathy.]({"type":"image" , "src" : "/sda/112392/Skyscraper_BristolMyersSquibb.jpg"})